Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Table 5 Estimation of MCID estimates in mRSS using Patient Global Assessment anchor for all participants

Patient Global Assessment	N	Unadjusted mean			Effect size
Patient Global Assessment	N	Mean	95% LCL	95% UCL	Effect size
Overall
Change ≤ − 50	8	− 3.75	− 7.69	0.19	− 0.35
−20 ≥ change > − 50 (MCID estimate for improvement)	35	− 4.06	− 6.66	− 1.45	− 0.38
− 20 < change < 20	123	− 2.94	− 3.92	− 1.96	− 0.27
20 ≤ change < 50	23	− 0.17	− 2.71	2.36	− 0.02
Change ≥ 50	6	1.5	− 2.94	5.94	0.14
Diffuse SSc
Change ≤ − 50	5	− 5.60	− 11.85	0.65	− 0.58
−20 ≥ change > − 50 (MCID estimate for improvement)	26	− 5.12	− 8.48	− 1.75	− 0.53
− 20 < change < 20	69	− 5.16	− 6.57	− 3.74	− 0.54
20 ≤ change < 50	16	− 0.56	− 4.25	3.12	− 0.06
Change ≥ 50	2	6.50	− 25.27	38.27	0.68
Limited SSc
Change ≤ − 50	3	− 0.67	− 5.84	4.50	− 0.19
− 20 ≥ change > − 50 (MCID estimate for improvement)	9	− 1.00	− 3.72	1.72	− 0.28
− 20 < change < 20	54	− 0.11	− 0.98	0.76	− 0.03
20 ≤ change < 50	7	0.71	− 1.40	2.83	0.20
Change ≥ 50	4	− 1.00	− 2.30	0.30	− 0.28

LCL lower confidence limit, MCID minimal clinically important difference, mRSS modified Rodnan Skin Score, SSc systemic sclerosis, UCL upper confidence limit

ISSN: 1478-6362